Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Silencing van het hepatitis B-virus S-gen door CRISPR‐gemedieerde base editing
feb 2020 | Hepatitis, Hepatologie, Virale infecties